Viridian Therapeutics, Inc./DE Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount
Viridian Therapeutics, Inc./DE (VRDN) had Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount of $127.20 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Payment Arrangement, Additional Disclosure
us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions · last filed 2026-08-06
- 2026-06-30: Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount $127.20M.
- 2026-03-31: Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount $139.50M.
- 2025-12-31: Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount $101.00M.
- 2025-09-30: Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount $103.30M.
| Period end | Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount |
|---|---|
| 2026-06-30 | $127.20M 10-Q · filed 2026-08-06 |
| 2026-03-31 | $139.50M 10-Q · filed 2026-05-05 |
| 2025-12-31 | $101.00M 10-K · filed 2026-02-26 |
| 2025-09-30 | $103.30M 10-Q · filed 2025-11-05 |
| 2025-06-30 | $106.30M 10-Q · filed 2025-08-06 |
| 2025-03-31 | $113.80M 10-Q · filed 2025-05-06 |
| 2024-12-31 | $83.50M 10-K · filed 2025-03-03 |
| 2024-09-30 | $87.10M 10-Q · filed 2024-11-12 |
| 2024-06-30 | $92.70M 10-Q · filed 2024-08-08 |
| 2024-03-31 | $92.30M 10-Q · filed 2024-05-08 |
| 2023-12-31 | $108.60M 10-K · filed 2024-02-27 |
| 2023-09-30 | $106.70M 10-Q · filed 2023-11-13 |
| 2023-06-30 | $121.20M 10-Q · filed 2023-08-08 |
| 2023-03-31 | $115.70M 10-Q · filed 2023-05-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 | |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |